IRIS
CIABATTINI, ANNALISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.913
NA - Nord America 4.775
AS - Asia 2.397
SA - Sud America 432
AF - Africa 40
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.564
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.698
RU - Federazione Russa 1.234
IT - Italia 899
CN - Cina 830
SG - Singapore 782
GB - Regno Unito 684
IE - Irlanda 633
BR - Brasile 369
SE - Svezia 315
DE - Germania 311
FI - Finlandia 232
UA - Ucraina 213
HK - Hong Kong 200
FR - Francia 186
VN - Vietnam 181
KR - Corea 165
IN - India 73
CA - Canada 42
ES - Italia 38
PL - Polonia 34
BD - Bangladesh 29
NL - Olanda 28
AR - Argentina 22
BE - Belgio 21
MX - Messico 21
JP - Giappone 19
AT - Austria 18
IQ - Iraq 16
UZ - Uzbekistan 16
CZ - Repubblica Ceca 14
ZA - Sudafrica 13
IR - Iran 12
EC - Ecuador 11
CI - Costa d'Avorio 10
LT - Lituania 10
TR - Turchia 10
CH - Svizzera 9
GR - Grecia 9
IL - Israele 9
AE - Emirati Arabi Uniti 7
ID - Indonesia 7
VE - Venezuela 7
SA - Arabia Saudita 6
BO - Bolivia 5
CL - Cile 5
PE - Perù 5
PK - Pakistan 5
PT - Portogallo 5
AZ - Azerbaigian 4
CO - Colombia 4
DO - Repubblica Dominicana 4
EG - Egitto 4
JO - Giordania 4
TH - Thailandia 4
AL - Albania 3
AU - Australia 3
KE - Kenya 3
MA - Marocco 3
NO - Norvegia 3
PH - Filippine 3
PY - Paraguay 3
RO - Romania 3
BG - Bulgaria 2
DK - Danimarca 2
DZ - Algeria 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
JM - Giamaica 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
TN - Tunisia 2
BB - Barbados 1
BH - Bahrain 1
ET - Etiopia 1
GD - Grenada 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.564
Salva come PNG Salva come JPEG
Città #
Dallas 709
Dublin 632
Southend 553
Fairfield 481
Singapore 457
Ashburn 393
Chandler 332
Moscow 330
Santa Clara 277
Siena 264
Beijing 231
Woodbridge 219
Hong Kong 196
Jacksonville 174
Hefei 170
Ann Arbor 161
Seattle 159
Seoul 158
Cambridge 155
Houston 151
Munich 144
Wilmington 140
Helsinki 112
Los Angeles 97
Princeton 97
New York 91
Milan 85
Rome 69
Dong Ket 68
Lappeenranta 64
Florence 58
Nanjing 58
São Paulo 36
Shanghai 33
Ho Chi Minh City 32
San Mateo 32
The Dalles 30
Hanoi 29
Buffalo 28
San Diego 27
London 25
Boardman 24
Menlo Park 22
Turku 22
Brussels 21
Düsseldorf 21
Nuremberg 21
Shenyang 21
Bengaluru 20
Council Bluffs 19
Redondo Beach 19
Tokyo 19
Chicago 18
Lancaster 18
Denver 17
Warsaw 17
Málaga 16
Columbus 15
Lauterbourg 15
Montreal 15
Nanchang 15
Belo Horizonte 14
Dearborn 14
Messina 14
Phoenix 14
San Francisco 14
Toronto 14
Washington 14
Fremont 13
Tashkent 13
Frankfurt am Main 12
Hebei 12
Portsmouth 12
Atlanta 11
Guangzhou 11
Kunming 11
Redwood City 11
Abidjan 10
Changsha 10
Chennai 10
Piscataway 10
Brno 9
Brooklyn 9
Curitiba 9
Poggibonsi 9
Rio de Janeiro 9
Tianjin 9
Amsterdam 8
Dhaka 8
Jiaxing 8
Jinan 8
Mumbai 8
Campinas 7
Naples 7
Norwalk 7
Orem 7
Bacoli 6
Boston 6
Brescia 6
Cape Town 6
Totale 8.322
Salva come PNG Salva come JPEG
Nome #
Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System 321
Vaginal immunization to elicit primary T-cell activation and dissemination 305
Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation 277
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study 275
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 272
Distribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in mice 260
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 257
Adoptive transfer of transgenic T cells to study mucosal adjuvants 250
Ebola vaccine R&D: Filling the knowledge gaps 244
Role of the microbiota in the modulation of vaccine immune responses 242
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 240
Characterization of the antigen-specific CD4+ T cell response induced by prime-boost strategies with CAF01 and CpG adjuvants administered by the intranasal and subcutaneous routes 231
Bacillus spores for vaccine delivery 228
In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii 221
Vaccination in the elderly: The challenge of immune changes with aging 218
Modulation of Primary Immune Response by Different Vaccine Adjuvants 213
Optimized protocol for the detection of multifunctional epitope-specific CD4+ T cells combining MHC-II tetramer and intracellular cytokine staining technologies 212
High rate of HDR in gene editing of p.(Thr158Met) MECP2 mutational hotspot 207
A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses 189
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 189
Transcriptomics of the vaccine immune response: Priming with adjuvant modulates recall innate responses after boosting 187
Long-term anti-bacterial immunity against systemic infection by Salmonella enterica serovar typhimurium elicited by a GMMA-based vaccine 185
B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy 184
Stimulation of human monocytes with the gram-positive vaccine vector Streptococcus gordonii 184
Intranasal immunization with vaccine vector Streptococcus gordonii elicits primed CD4(+) and CD8(+) T cells in the genital and intestinal tracts 183
Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA. 179
CD4+ T Cell Priming as Biomarker to Study Immune Response to Preventive Vaccines 177
Recombinant Haemagglutinin Derived From the Ciliated Protozoan Tetrahymena thermophila Is Protective Against Influenza Infection 174
Immunization with the conjugate vaccine Vi-CRM(197) against Salmonella Typhi induces Vi-specific mucosal and systemic immune responses in mice 172
Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine 169
Antibody response and protection from challenge in mice immunized with recombinant Streptococcus gordonii expressing fragment C of tetanus toxin 167
Prime-boost strategies in mucosal immunization affect local IgA production and the type of th response 166
Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice 164
Comparison of Immune Responses Elicited by BNT162b2, mRNA-1273 and ChAdOx1 COVID-19 Vaccines. 161
In vivo primary activation of CD4+ and CD8+ T-cells following mucosal vaccination 160
Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population 159
Oral priming of mice by recombinant spores of Bacillus subtilis 156
CTA1-DD has an Adjuvant Effect Once Expressed on the Surface of the Gram-Positive Bacterium Streptococcus gordonii 156
Primary T-cell response to mucosal vaccination 156
Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity? 155
Induzione primaria di linfociti T CD4 nel tessuto linfoide associato al naso (NALT) in seguito ad immunizzazione con Streptococcus gordonii 154
Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge 154
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients 152
Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration 152
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability 151
Computational Analysis of Multiparametric Flow Cytometric Data to Dissect B Cell Subsets in Vaccine Studies 151
Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria 150
From bivariate to multivariate analysis of cytometric data: overview of computational methods and their application in vaccination studies 150
Surface display of recombinant proteins on Bacillus subtilis spores 149
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination 149
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound? 148
Recombinant gram-positive bacteria for intranasal immunization: characterization of the murine nasal-associated lymphoid tissue and study of local T-cell priming 148
Nasal and vaginal routes of immunization for CD4+ and CD8+ T-cell priming 146
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine 146
Spike-Specific memory B cell response in hematopoietic cell transplantation recipients following multiple mRNA-1273 vaccinations: a longitudinal observational study 141
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine 131
Correction to: High rate of HDR in gene editing of p.(Thr158Met) MECP2 mutational hotspot 127
Transcriptomic analysis after SARS-CoV-2 mRNA vaccination reveals a specific gene signature in low-responder hemodialysis patients 122
Oral priming of mice using recombinant spores of Bacillus subtilis 122
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein 121
Primary activation of CD4+ and CD8+ T cells following mucosal vaccination with recombinant bacteria 120
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 116
Expression of immunomodulating molecules on the surface of the vaccine vector Streptococcus gordonii 113
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant 110
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study 110
Vaccinazione anti SARSCov2 in una coorte di pazienti sottoposti a trapianto di cuore o di polmone: risposta umorale a dosi booster 109
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 109
Using IFN-gamma release assay to confirm tuberculin skin test improves the screening of latent tuberculosis infection in Italian healthcare workers 105
null 102
Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies. 101
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP 97
Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2 97
Successivi booster vaccinali contro SARS-CoV-2: risposta umorale in pazienti sottoposti a trapianto di cuore o di polmone 96
Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach 93
Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine. 91
Longitudinal profiling of spike-specific antibody and B cell responses following mRNA-1273 SARS-CoV-2 vaccination in hematopoietic cell transplantation recipients 79
Totale 12.757
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.667
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.667
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021775 0 0 0 0 0 100 41 134 92 195 96 117
2021/2022837 64 127 43 59 29 14 44 28 44 80 115 190
2022/20231.223 77 142 173 136 103 220 41 104 88 31 81 27
2023/20241.202 33 34 100 79 55 307 367 43 24 65 25 70
2024/20252.606 80 97 271 138 313 166 144 161 269 111 244 612
2025/20263.722 459 796 593 763 1.079 32 0 0 0 0 0 0
Totale 12.757